1  hours (P = .018) were associated with early defervescence.

2 val [CI] .11-.58) were associated with early defervescence.

3 care unit (ICU) LOS, inflammation, and fever defervescence.

4 ial, short duration of bacteremia, and rapid defervescence.

5 ow-up, and were worst in the severe group at defervescence.

6 ation starting from the early febrile to the defervescence and convalescent stages of the infection.

7 t because appropriate therapy leads to rapid defervescence and cure.

8 t with doxycycline usually results in prompt defervescence and cure.

9 celerated resolution of clinical illness and defervescence and decreased both the incidence of otitis

10 used Kaplan-Meier curves to evaluate time to defervescence and hospital discharge.

11 mens in terms of therapy success, defined as defervescence and improvement in clinical status during

12  tonometry are being performed at enrolment, defervescence, and follow-up FINDINGS: To date, 167 pati

13 tment was not associated with ICU LOS, fever defervescence by day 3, or normalization of inflammatory

14 heter removal with delayed replacement after defervescence [Delay group], 37 cases).

15                                      Time to defervescence in 17 patients treated with ceftriaxone an

16 ge occurs at the time of viral clearance and defervescence in dengue hemorrhagic fever.

17 efervescence without regimen change, time to defervescence, infectious complications, and recurrent f

18 tocilizumab in 13 subjects resulted in rapid defervescence (median, 4 hr) and clinical improvement.

19 ed with ceftriaxone monotherapy, the time to defervescence was 6.6 days (+/- 1.8; P < .001).

20 ; in outpatients with fever and neutropenia, defervescence without regimen change, time to defervesce